0000899243-21-011978.txt : 20210316 0000899243-21-011978.hdr.sgml : 20210316 20210316171343 ACCESSION NUMBER: 0000899243-21-011978 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210313 FILED AS OF DATE: 20210316 DATE AS OF CHANGE: 20210316 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cao Yanling CENTRAL INDEX KEY: 0001789665 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39067 FILM NUMBER: 21746943 MAIL ADDRESS: STREET 1: SUITE 1518, TWO PACIFIC PLACE STREET 2: 88 QUEENSWAY CITY: HONG KONG STATE: K3 ZIP: 00000 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Viela Bio, Inc. CENTRAL INDEX KEY: 0001734517 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 1 MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 BUSINESS PHONE: 240-558-0038 MAIL ADDRESS: STREET 1: 1 MEDIMMUNE WAY CITY: GAITHERSBURG STATE: MD ZIP: 20878 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-03-13 1 0001734517 Viela Bio, Inc. VIE 0001789665 Cao Yanling C/O VIELA BIO, INC., ONE MEDIMMUNE WAY, FIRST FLOOR, AREA TWO GAITHERSBURG MD 20878 1 0 1 0 Common Stock 2021-03-13 4 D 0 8322353 53.00 D 0 I Held by Boundless Meadow Limited Reflects disposition of Issuer common stock in connection with the consummation of the transactions contemplated by the Agreement and Plan of Merger, dated January 31, 2021 (the "Merger Agreement"), by and among the Issuer, Horizon Therapeutics USA, Inc., Teiripic Merger Sub, Inc. ("Purchaser"), and for certain purposes, Horizon Therapeutics plc, including the completion on March 13, 2021 of a tender offer to purchase all of the outstanding shares of Issuer common stock at a price of $53.00 per share in cash, without interest, less any required withholding taxes (the "Offer Price"), and the consummation of the merger (the "Merger") between the Issuer and Purchaser on March 15, 2021. Pursuant to the Merger Agreement, as of the effective time of the Merger, each outstanding share of Issuer common stock was cancelled in exchange for the right to receive an amount equal to the Offer Price. Boundless Meadow Limited is wholly owned by Boyu Capital Fund III. L.P., which is a fund to which Boyu Capital Advisory Co. Limited provides non-discretionary investment advisory services. Mr. Cao is a Partner of Boyu Capital Advisory Co. Limited, and may be deemed to beneficially own the shares held by Boundless Meadow Limited. Mr. Cao disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein, if any. /s/ Yanling Cao 2021-03-16